Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 All time
- Disclosed funding
- $19.1B 398 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CB CORE BiomedicineCompany profile Developing the next generation of precision medicines by going beyond genomics. Developing the next generation of precision medicines by going beyond genomics. | $21M | Series A | Biotech | United States | Investors | |
| TP Torrey Pines MedicineCompany profile Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases | Undisclosed | Pre-SeedPre-seed | Biotech | China | Investors | |
| VD Vivid DxCompany profile Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions | $15M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| M MiraeCompany profile AI-driven continuous care platform for autoimmune disease and other complex chronic conditions AI-driven continuous care platform for autoimmune disease and other complex chronic conditions | $5.4M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| MT Moa TechnologyCompany profile An agricultural biotechnology company focused on discovering novel mode of action herbicides An agricultural biotechnology company focused on discovering novel mode of action herbicides | £22.2M | Series CSeries C+ | Biotech, Agritech | United Kingdom | Investors | |
| TA Tikva AllocellCompany profile Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors | $8M | Series A | Biotech | Singapore | Investors | |
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors | |
| CT Crystalys TherapeuticsCompany profile Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout | $130M | Series B | Biotech | United States | Investors | |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed | |
| RN Rege Nephro CoCompany profile Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options | $10.6M | Series CSeries C+ | Biotech | Japan | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.